{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:56:40Z","timestamp":1793321800143,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T00:00:00Z","timestamp":1741392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Denosumab produces a continuous increase in bone mineral density over ten years, associated with a low risk of vertebral and non-vertebral fractures. Denosumab is well tolerated and easy to manage in daily clinical practice. For all these reasons, this treatment has a huge success. On the other hand, discontinuation of treatment is associated with a severe rebound effect including a sharp increase in bone turnover markers, loss of the bone density gained and a risk of nearly 20% of multiple vertebral fractures in postmenopausal women. High doses of potent bisphosphonates are needed to maintain bone turnover markers in the low range of premenopausal women, to mitigate this rebound effect. Prolonged treatment with denosumab is associated with a greater rebound effect and increases the risk of an early rebound effect. The occurrence of rare side effects such as osteonecrosis of the jaw or atypical femoral fracture, as well as the onset of severe renal failure, leave clinicians at a therapeutic impasse. Continuing denosumab or switching to bisphosphonates remains suboptimal and, currently, no evidence clarifies the optimal treatment approach for these patients. The aim of this review is to give a very practical clinical approach to the use of denosumab (duration of treatment), and to the management of rebound effect and possible adverse effects.<\/jats:p>","DOI":"10.1007\/s40520-025-02991-z","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T21:50:48Z","timestamp":1741384248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Denosumab for osteoporosis treatment: when, how, for whom, and for how long. A pragmatical approach"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3684-2376","authenticated-orcid":false,"given":"Olivier","family":"Lamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8792-8199","authenticated-orcid":false,"given":"Judith","family":"Everts-Graber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6512-6008","authenticated-orcid":false,"given":"Elena","family":"Gonzalez Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,8]]},"reference":[{"key":"2991_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30138-9","author":"HG Bone","year":"2017","unstructured":"Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 Years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(17)30138-9. 5:513\u2010523","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2991_CR2","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jbmr.3722","volume":"34","author":"S Ferrari","year":"2019","unstructured":"Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwi\u0144ski E et al (2019) Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Min Res 34:1033\u20131040. https:\/\/doi.org\/10.1002\/jbmr.3722","journal-title":"J Bone Min Res"},{"key":"2991_CR3","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O, The Swiss Denosumab Study Group (2021) Fractures after denosumab discontinuation: a retrospective study of 797 cases. J Bone Min Res 36:1717\u20131728. https:\/\/doi.org\/10.1002\/jbmr.4335","journal-title":"J Bone Min Res"},{"key":"2991_CR4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/jbmr.3370","volume":"33","author":"O Lamy","year":"2018","unstructured":"Lamy O, Gonzalez-Rodriguez E (2018) Underestimation of vertebral fractures after denosumab discontinuation. J Bone Min Res 33:547. https:\/\/doi.org\/10.1002\/jbmr.3370","journal-title":"J Bone Min Res"},{"key":"2991_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1080\/14397595.2020.1769895","volume":"31","author":"K Ebina","year":"2021","unstructured":"Ebina K, Hashimoto J, Kashii M, Hirao M, Miyama A, Nakaya H et al (2021) Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis. Mod Rheumatol 31:485\u2013492. https:\/\/doi.org\/10.1080\/14397595.2020.1769895","journal-title":"Mod Rheumatol"},{"key":"2991_CR6","doi-asserted-by":"publisher","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","volume":"144","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: A real-world observational study. Bone 144:115830. https:\/\/doi.org\/10.1016\/j.bone.2020.115830","journal-title":"Bone"},{"key":"2991_CR7","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS S\u00f8lling","year":"2021","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Min Res 36:1245\u20131254. https:\/\/doi.org\/10.1002\/jbmr.4305","journal-title":"J Bone Min Res"},{"key":"2991_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1002\/jbmr.3110","volume":"32","author":"AD Anastasilakis","year":"2017","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O (2017) Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Min Res 32:1291\u20131296. https:\/\/doi.org\/10.1002\/jbmr.3110","journal-title":"J Bone Min Res"},{"key":"2991_CR9","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses. J Bone Min Res 37:2112\u20132120. https:\/\/doi.org\/10.1002\/jbmr.4705","journal-title":"J Bone Min Res"},{"key":"2991_CR10","doi-asserted-by":"publisher","first-page":"141225919","DOI":"10.3389\/fphar.2023.1225919","volume":"1","author":"S Su","year":"2023","unstructured":"Su S, Wu L, Zhou G, Peng L, Zhao H, Wang X et al (2023) Indication and adverse event profiles of denosumab and Zoledronic acid: based on U.S. FDA adverse event reporting system (FAERS). Front Pharmacol 1:141225919. https:\/\/doi.org\/10.3389\/fphar.2023.1225919","journal-title":"Front Pharmacol"},{"key":"2991_CR11","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1002\/jbmr.1613","volume":"27","author":"GA Block","year":"2012","unstructured":"Block GA, Bone HG, Fang L, Lee E, Padhi D (2012) A single-dose study of denosumab in patients with various degrees of renal impairment. J Bone Min Res 27:1471\u20131479. https:\/\/doi.org\/10.1002\/jbmr.1613","journal-title":"J Bone Min Res"},{"key":"2991_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1159\/000380960","volume":"41","author":"V Dave","year":"2015","unstructured":"Dave V, Chiang CY, Booth J, Mount PF (2015) Hypocalcemia post denosumab in patients with chronic kidney disease stage 4\u20135. Am J Nephrol 41:129\u2013137. https:\/\/doi.org\/10.1159\/000380960","journal-title":"Am J Nephrol"},{"key":"2991_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2023.28239","volume":"331","author":"ST Bird","year":"2024","unstructured":"Bird ST, Smith ER, Gelperin K, Jung TH, Thompson A, Kambhampati R et al (2024) Severe hypocalcemia with denosumab among older female dialysis-dependent patients. JAMA 331:491\u2013499. https:\/\/doi.org\/10.1001\/jama.2023.28239","journal-title":"JAMA"},{"key":"2991_CR14","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/ndt\/gfaa192","volume":"36","author":"P Evenepoel","year":"2021","unstructured":"Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH et al (2021) European consensus statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transpl 36:42\u201359. https:\/\/doi.org\/10.1093\/ndt\/gfaa192","journal-title":"Nephrol Dial Transpl"},{"key":"2991_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1056\/NEJMoa044459","volume":"354","author":"MR McClung","year":"2006","unstructured":"McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821\u2013831. https:\/\/doi.org\/10.1056\/NEJMoa044459","journal-title":"N Engl J Med"},{"key":"2991_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/s41584-024-01094-9","volume":"20","author":"NR Fuggle","year":"2024","unstructured":"Fuggle NR, Beaudart C, Bruy\u00e8re O, Abrahamsen B, Al-Daghri N, Burlet N et al (2024) Evidence-Based guideline for the management of osteoporosis in men. Nat Rev Rheumatol 20:241\u2013251. https:\/\/doi.org\/10.1038\/s41584-024-01094-9","journal-title":"Nat Rev Rheumatol"},{"key":"2991_CR17","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1002\/art.42646","volume":"75","author":"MB Humphrey","year":"2023","unstructured":"Humphrey MB, Russell L, Danila MI, Fink HA, Guyatt G, Cannon M et al (2023) 2022 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol 75:2405\u20132019. https:\/\/doi.org\/10.1002\/art.42646","journal-title":"Arthritis Rheumatol"},{"key":"2991_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","volume":"386","author":"M Gnant","year":"2015","unstructured":"Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R et al (2015) Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double-blind, placebo-controlled trial. Lancet 386:433\u2013443. https:\/\/doi.org\/10.1016\/S0140-6736(15)60995-3","journal-title":"Lancet"},{"key":"2991_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1056\/nejmoa0809003","volume":"361","author":"MR Smith","year":"2009","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N, Feldman R, Tammela TL, Saad F et al (2009) Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 361:745\u2013755. https:\/\/doi.org\/10.1056\/nejmoa0809003","journal-title":"N Engl J Med"},{"key":"2991_CR20","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(15)61120-5","volume":"386","author":"BZ Leder","year":"2015","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM et al (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 386:1147\u20131155. https:\/\/doi.org\/10.1016\/S0140-6736(15)61120-5","journal-title":"Lancet"},{"key":"2991_CR21","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/nejmoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/nejmoa1607948","journal-title":"N Engl J Med"},{"key":"2991_CR22","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA et al (2016) Denosumab or Zoledronic acid in postmenopausal women with osteoporosis previously treated with oral bisphosphonates. J Clin Endocrinol Metab 101:3163\u20133170. https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J Clin Endocrinol Metab"},{"key":"2991_CR23","doi-asserted-by":"publisher","first-page":"516","DOI":"10.7326\/M20-0882","volume":"173","author":"H Lyu","year":"2020","unstructured":"Lyu H, Yoshida K, Zhao SS, Wei J, Zeng C, Tedeschi SK et al (2020) Delayed denosumab injections and fracture risk among patients with osteoporosis: A population-based cohort study. Ann Intern Med 173:516\u2013526. https:\/\/doi.org\/10.7326\/M20-0882","journal-title":"Ann Intern Med"},{"key":"2991_CR24","doi-asserted-by":"publisher","first-page":"116925","DOI":"10.1016\/j.bone.2023.116925","volume":"177","author":"KR Cruchelow","year":"2023","unstructured":"Cruchelow KR, Peter ME, Chakrabarti A, Gipson HM, Gregory WT, DeClercq J et al (2023) Denosumab treatment lapses, discontinuation, and off-treatment fracture risk: A retrospective study of patients with osteoporosis in a real-world clinical setting. Bone 177:116925. https:\/\/doi.org\/10.1016\/j.bone.2023.116925","journal-title":"Bone"},{"key":"2991_CR25","doi-asserted-by":"publisher","first-page":"217","DOI":"10.11005\/jbm.2022.29.4.217","volume":"29","author":"AC Inojosa","year":"2022","unstructured":"Inojosa AC, Mendes L, Bandeira L, Bandeira F (2022) The role of bisphosphonates prior to denosumab treatment on rebound fractures: A Mini review. J Bone Metab 29:217\u2013223. https:\/\/doi.org\/10.11005\/jbm.2022.29.4.217","journal-title":"J Bone Metab"},{"key":"2991_CR26","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.metabol.2015.06.018","volume":"64","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Efstathiadou ZA, Savvidis M, Sakellariou GT, Papatheodorou A et al (2015) Denosumab in treatment-na\u00efve and pre-treated with Zoledronic acid postmenopausal women with low bone mass: effect on bone mineral density and bone turnover markers. Metabolism 64:1291\u20131297. https:\/\/doi.org\/10.1016\/j.metabol.2015.06.018","journal-title":"Metabolism"},{"key":"2991_CR27","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1007\/s00198-017-4080-6","volume":"28","author":"B Uebelhart","year":"2017","unstructured":"Uebelhart B, Rizzoli R, Ferrari SL (2017) Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. Osteoporos Int 28:2701\u20132705. https:\/\/doi.org\/10.1007\/s00198-017-4080-6","journal-title":"Osteoporos Int"},{"key":"2991_CR28","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, Martin JS, McClung MR, Siris ES, Eastell R, Reid IR et al (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. https:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"2991_CR29","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","volume":"296","author":"DM Black","year":"2006","unstructured":"Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA et al (2006) Effects of continuing or stopping alendronate after 5 years of treatment. JAMA 296:2927\u20132938. https:\/\/doi.org\/10.1001\/jama.296.24.2927","journal-title":"JAMA"},{"key":"2991_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/jbmr.1494","volume":"27","author":"DM Black","year":"2012","unstructured":"Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F et al (2012) The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal fracture trial (PFT). J Bone Min Res 27:243\u2013254. https:\/\/doi.org\/10.1002\/jbmr.1494","journal-title":"J Bone Min Res"},{"key":"2991_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19:307\u2013317. https:\/\/doi.org\/10.1038\/s41584-023-00935-3","journal-title":"Nat Rev Rheumatol"},{"key":"2991_CR32","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1002\/jbmr.2480","volume":"30","author":"MS Ominsky","year":"2015","unstructured":"Ominsky MS, Libanati C, Niu QT, Boyce RW, Kostenuik PJ, Wagman R et al (2015) Sustained modeling-based bone formation during adulthood in cynomolgus monkeys May contribute to continuous BMD gains with denosumab. J Bone Min Res 30:1280\u20131289. https:\/\/doi.org\/10.1002\/jbmr.2480","journal-title":"J Bone Min Res"},{"issue":"3","key":"2991_CR33","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1210\/jc.2012-3680","volume":"98","author":"EM Lewiecki","year":"2013","unstructured":"Lewiecki EM, Cummings SR, Cosman F (2013) Treat-to-target for osteoporosis: is now the time? J Clin Endocrinol Metab 98(3):946\u2013953. https:\/\/doi.org\/10.1210\/jc.2012-3680","journal-title":"J Clin Endocrinol Metab"},{"key":"2991_CR34","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/jbmr.1854","volume":"28","author":"SR Cummings","year":"2013","unstructured":"Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM (2013) Goal-directed treatment of osteoporosis. J Bone Min Res 28:433\u2013438. https:\/\/doi.org\/10.1002\/jbmr.1854","journal-title":"J Bone Min Res"},{"key":"2991_CR35","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.jocd.2022.03.001","volume":"25","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Lehmann T (2022) Bone mass gains after one denosumab injection followed by zoledronate. J Clin Densitom 25:293\u2013298. https:\/\/doi.org\/10.1016\/j.jocd.2022.03.001","journal-title":"J Clin Densitom"},{"key":"2991_CR36","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1210\/jc.2010-1805","volume":"96","author":"PD Miller","year":"2011","unstructured":"Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL et al (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96:394\u2013402. https:\/\/doi.org\/10.1210\/jc.2010-1805","journal-title":"J Clin Endocrinol Metab"},{"key":"2991_CR37","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10549-019-05458-8","volume":"179","author":"E Gonzalez-Rodriguez","year":"2019","unstructured":"Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Zaman K, Lamy O (2019) Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors. Breast Cancer Res Treat 179:153\u2013159. https:\/\/doi.org\/10.1007\/s10549-019-05458-8","journal-title":"Breast Cancer Res Treat"},{"key":"2991_CR38","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA et al (2021) The duration of denosumab treatment and the efficacy of zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106:e4155\u2013e4162. https:\/\/doi.org\/10.1210\/clinem\/dgab321","journal-title":"J Clin Endocrinol Metab"},{"key":"2991_CR39","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R, Ebeling PE, Jan De Beur S, Langdahl S et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Min Res 39:1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Min Res"},{"key":"2991_CR40","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00198-023-06932-2","volume":"35","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Tsai JN, Lee H, Sassana-Khadka G, Jordan M, Ryan S et al (2024) The comparison of alendronate and raloxifene after denosumab (CARD) study: A comparative efficacy trial. Osteoporos Int 35:255\u2013263. https:\/\/doi.org\/10.1007\/s00198-023-06932-2","journal-title":"Osteoporos Int"},{"key":"2991_CR41","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS Solling","year":"2020","unstructured":"Solling AS, Harslof T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Min Res 35:1858\u20131870. https:\/\/doi.org\/10.1002\/jbmr.4098","journal-title":"J Bone Min Res"},{"key":"2991_CR42","doi-asserted-by":"publisher","first-page":"116764","DOI":"10.1016\/j.bone.2023.116764","volume":"172","author":"G Liebich","year":"2023","unstructured":"Liebich G, Lamy O, Aubry-Rozier B, Gonzalez-Rodriguez E (2023) Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. ReoLaus Study Bone 172:116764. https:\/\/doi.org\/10.1016\/j.bone.2023.116764","journal-title":"ReoLaus Study Bone"},{"key":"2991_CR43","doi-asserted-by":"publisher","first-page":"e1817","DOI":"10.1210\/clinem\/dgae224","volume":"109","author":"G Grassi","year":"2024","unstructured":"Grassi G, Ghielmetti A, Zampogna M, Chiodini I, Arosio M, Mantovani G et al (2024) Zoledronate after denosumab discontinuation: is repeated administrations more effective than single infusion? J Clin Endocrinol Metab 109:e1817\u2013e1826. https:\/\/doi.org\/10.1210\/clinem\/dgae224","journal-title":"J Clin Endocrinol Metab"},{"key":"2991_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s00198-011-1780-1","volume":"23","author":"N Freemantle","year":"2012","unstructured":"Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S et al (2012) Final results of the DAPS (Denosumab adherence preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int 23:317\u2013326. https:\/\/doi.org\/10.1007\/s00198-011-1780-1","journal-title":"Osteoporos Int"},{"key":"2991_CR45","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Min Res 35:1207\u20131215. https:\/\/doi.org\/10.1002\/jbmr.3962","journal-title":"J Bone Min Res"},{"key":"2991_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00198-022-06648-9","volume":"34","author":"T Tutaworn","year":"2023","unstructured":"Tutaworn T, Nieves JW, Wang Z, Levin JE, Yoo JE, Lane JM (2023) Bone loss after denosumab discontinuation is prevented by alendronate and Zoledronic acid but not risedronate: a retrospective study. Osteoporos Int 34:573\u2013584. https:\/\/doi.org\/10.1007\/s00198-022-06648-9","journal-title":"Osteoporos Int"},{"key":"2991_CR47","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.jbspin.2021.105219","volume":"88","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A (2021) Effects of prior osteoporosis treatment on 12-month treatment response of Romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine 88:105219. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"key":"2991_CR48","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00198-018-04820-8","volume":"30","author":"O Lamy","year":"2019","unstructured":"Lamy O, Fern\u00e1ndez-Fern\u00e1ndez E, Monjo-Henry I, Stoll D, Aubry-Rozier B, Benavent-N\u00fa\u00f1ez D et al (2019) Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. Osteoporos Int 30:1111\u20131115. https:\/\/doi.org\/10.1007\/s00198-018-04820-8","journal-title":"Osteoporos Int"},{"key":"2991_CR49","doi-asserted-by":"publisher","first-page":"116498","DOI":"10.1016\/j.bone.2022.116498","volume":"163","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Reichenbach S, Gahl B, H\u00e4uselmann HJ, Ziswiler HR, Studer U et al (2022) Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: observations in a Real-World setting. Bone 163:116498. https:\/\/doi.org\/10.1016\/j.bone.2022.116498","journal-title":"Bone"},{"key":"2991_CR50","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00223-018-0394-4","volume":"103","author":"AW Popp","year":"2018","unstructured":"Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K (2018) Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with Long-Term denosumab treatment for osteoporosis. Calcif Tissue Int 103:50\u201354. https:\/\/doi.org\/10.1007\/s00223-018-0394-4","journal-title":"Calcif Tissue Int"},{"key":"2991_CR51","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11914-019-00502-4","volume":"17","author":"O Lamy","year":"2019","unstructured":"Lamy O, Stoll D, Aubry-Rozier B, Gonzalez Rodriguez E (2019) Stopping denosumab. Curr Osteoporos 17:8\u201315. https:\/\/doi.org\/10.1007\/s11914-019-00502-4","journal-title":"Curr Osteoporos"},{"key":"2991_CR52","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00223-020-00785-1","volume":"108","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Polyzos SA, Yavropoulou MP, Appelman-Dijkstra NM, Ntenti C, Mandanas S et al (2021) Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation. Calcif Tissue Int 108:587\u2013594. https:\/\/doi.org\/10.1007\/s00223-020-00785-1","journal-title":"Calcif Tissue Int"},{"key":"2991_CR53","doi-asserted-by":"publisher","first-page":"dgaa756","DOI":"10.1210\/clinem\/dgaa756","volume":"26","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E et al (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab Oct 26:dgaa756. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab Oct"},{"key":"2991_CR54","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1359\/jbmr.070809","volume":"22","author":"EM Lewiecki","year":"2009","unstructured":"Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y et al (2009) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Min Res 22:1832\u20131841. https:\/\/doi.org\/10.1359\/jbmr.070809","journal-title":"J Bone Min Res"},{"key":"2991_CR55","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s12020-022-03230-5","volume":"80","author":"AA Khan","year":"2023","unstructured":"Khan AA, AbuAlrob H, M\u2019Hiri I, Ali DS, Dandurand K, Said H et al (2023) Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60\u00a0mg dose: a prospective observational study. Endocrine 80:647\u2013657. https:\/\/doi.org\/10.1007\/s12020-022-03230-5","journal-title":"Endocrine"},{"key":"2991_CR56","doi-asserted-by":"publisher","first-page":"e10731","DOI":"10.1002\/jbm4.10731","volume":"7","author":"M Laroche","year":"2023","unstructured":"Laroche M, Couture G, Degboe Y (2023) Discontinuation of denosumab: gradual decrease in doses preserves half of the bone mineral density gain at the lumbar spine. JBMR Plus 7:e10731. https:\/\/doi.org\/10.1002\/jbm4.10731","journal-title":"JBMR Plus"},{"key":"2991_CR57","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ecl.2024.08.002","volume":"53","author":"S Jain","year":"2024","unstructured":"Jain S (2024) Prevention and management of denosumab discontinuation rebound fractures. Endocrinol Metab Clin North Am 53:559\u2013583. https:\/\/doi.org\/10.1016\/j.ecl.2024.08.002","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2991_CR58","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.bonr.2020.100288","volume":"13","author":"M Kashii","year":"2020","unstructured":"Kashii M, Ebina K, Kitaguchi K, Yoshikawa H (2020) A Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: A case report. Bone Rep 13:100288. https:\/\/doi.org\/10.1016\/j.bonr.2020.100288","journal-title":"Bone Rep"},{"key":"2991_CR59","doi-asserted-by":"publisher","first-page":"105754","DOI":"10.1016\/j.jbspin.2024.105754","volume":"91","author":"M Krikelis","year":"2024","unstructured":"Krikelis M, Gazi S, Trovas G, Makris K, Chronopoulos E, Tournis S (2024) Progression of multiple vertebral fractures after denosumab discontinuation under treatment with Romosozumab. A case-report. Joint Bone Spine 91:105754. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105754","journal-title":"Joint Bone Spine"},{"key":"2991_CR60","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jocd.2020.10.014","volume":"24","author":"AD Anastasilakis","year":"2021","unstructured":"Anastasilakis AD, Trovas G, Balanika A, Polyzos SA, Makras P, Tournis S (2021) Progression of rebound-associated vertebral fractures following denosumab discontinuation despite reinstitution of treatment: suppressing increased bone turnover May not be enough. J Clin Densitom 24:338\u2013340. https:\/\/doi.org\/10.1016\/j.jocd.2020.10.014","journal-title":"J Clin Densitom"},{"key":"2991_CR61","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s11657-019-0676-0","volume":"15","author":"R Niimi","year":"2020","unstructured":"Niimi R, Kono T, Nishihara A, Hasegawa M, Kono T, Sudo A (2020) Second rebound-associated vertebral fractures after denosumab discontinuation. Arch Osteoporos 15:7. https:\/\/doi.org\/10.1007\/s11657-019-0676-0","journal-title":"Arch Osteoporos"},{"key":"2991_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4132-y","author":"PA Eiken","year":"2017","unstructured":"Eiken PA, Prieto-Alhambra D, Eastell R, Abrahamsen B (2017) Surgically treated osteonecrosis and osteomyelitis of the jaw and oral cavity in patients highly adherent to alendronate treatment: a nationwide user\u2010only cohort study including over 60,000 alendronate users. Osteoporos Int. https:\/\/doi.org\/10.1007\/s00198-017-4132-y. 28:2921\u20102928","journal-title":"Osteoporos Int"},{"key":"2991_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/pds.3292","volume":"21","author":"P Tennis","year":"2012","unstructured":"Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C et al (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810\u2013817. https:\/\/doi.org\/10.1002\/pds.3292","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2991_CR64","doi-asserted-by":"publisher","first-page":"e326","DOI":"10.4317\/medoral.23324","volume":"25","author":"A Limones","year":"2020","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA, Helm A, Bornstein MM, Molinero-Mourelle P (2020) Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: A systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal 25:e326\u2013e336. https:\/\/doi.org\/10.4317\/medoral.23324","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"2991_CR65","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.joms.2022.10.014","volume":"81","author":"A Colella","year":"2023","unstructured":"Colella A, Yu E, Sambrook P, Hughes T, Goss A (2023) What is the risk of developing osteonecrosis following dental extractions for patients on denosumab for osteoporosis?? J Oral Maxillofac Surg 81:232\u2013237. https:\/\/doi.org\/10.1016\/j.joms.2022.10.014","journal-title":"J Oral Maxillofac Surg"},{"key":"2991_CR66","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jbmr.4472","volume":"37","author":"J Everts-Graber","year":"2022","unstructured":"Everts-Graber J, Lehmann D, Burkard JP, Schaller B, Gahl B, H\u00e4uselmann HJ et al (2022) Risk of osteonecrosis of the jaw under denosumab compared to bisphosphonates in patients with osteoporosis. J Bone Min Res 37:340\u2013348. https:\/\/doi.org\/10.1002\/jbmr.4472","journal-title":"J Bone Min Res"},{"key":"2991_CR67","doi-asserted-by":"publisher","first-page":"4763","DOI":"10.1007\/s00520-021-06018-x","volume":"2","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Mouri M, Tomita H, Hirabatake M, Ikemura M, Muroi N et al (2021) Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or Zoledronic acid for bone metastases. Support Care Cancer 2:4763\u20134772. https:\/\/doi.org\/10.1007\/s00520-021-06018-x","journal-title":"Support Care Cancer"},{"key":"2991_CR68","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1056\/NEJMoa1916525","volume":"383","author":"DM Black","year":"2020","unstructured":"Black DM, Geiger EJ, Eastell R, Vittinghoff E, Li BH, Ryan DS et al (2020) Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 383:743\u2013753. https:\/\/doi.org\/10.1056\/NEJMoa1916525","journal-title":"N Engl J Med"},{"key":"2991_CR69","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1210\/jc.2016-1801","volume":"101","author":"PD Miller","year":"2016","unstructured":"Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA et al (2016) Denosumab or Zoledronic acid in postmenopausal women with osteoporosis previously Trea Ted with oral bisphosphonates. J Clin Endocrinol Metabol 101:3163\u20133170. https:\/\/doi.org\/10.1210\/jc.2016-1801","journal-title":"J Clin Endocrinol Metabol"},{"key":"2991_CR70","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1002\/art.40874","volume":"71","author":"KG Saag","year":"2019","unstructured":"Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J et al (2019) Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a Twenty four\u2013month randomized, double-blind, double-dummy trial. Arthritis Rheumatol 71:1174\u20131184. https:\/\/doi.org\/10.1002\/art.40874","journal-title":"Arthritis Rheumatol"},{"key":"2991_CR71","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ecl.2024.08.007","volume":"53","author":"RAY Alnajmi","year":"2024","unstructured":"Alnajmi RAY, Ali DS, Khan AA (2024) Diagnosis and management of atypical femoral fractures and Medication-Related osteonecrosis of the jaw in patients with osteoporosis. Endocrinol Metab Clin North Am 53:607\u2013618. https:\/\/doi.org\/10.1016\/j.ecl.2024.08.007","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2991_CR72","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","volume":"105","author":"E Tsourdi","year":"2017","unstructured":"Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Gua\u00f1abens N et al (2017) Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone 105:11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2017.08.003","journal-title":"Bone"},{"key":"2991_CR73","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1210\/clinem\/dgz295","volume":"105","author":"DM van de Laarschot","year":"2020","unstructured":"van de Laarschot DM, McKenna MJ, Abrahamsen B, Langdahl B, Cohen-Solal M, Gua\u00f1abens N et al (2020) Medical management of patients after atypical femur fractures: a systematic review and recommendations from the European calcified tissue society. J Clin Endocrinol Metabol 105:1682\u20131699. https:\/\/doi.org\/10.1210\/clinem\/dgz295","journal-title":"J Clin Endocrinol Metabol"}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-02991-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40520-025-02991-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40520-025-02991-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:45:01Z","timestamp":1772606701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40520-025-02991-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,8]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1007\/s40520-025-02991-z","relation":{},"ISSN":["1720-8319"],"issn-type":[{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,8]]},"assertion":[{"value":"27 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"70"}}